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Abstract
Background: Vitamin A and its derivatives, the retinoids, are essential for normal embryonic
development and maintenance of cell differentiation. β,  β-carotene 15,15'-monooxygenase 1
(BCMO1) catalyzes the central cleavage of β-carotene to all-trans retinal and is the key enzyme in
the intestinal metabolism of carotenes to vitamin A. However, human and various rodent species
show markedly different efficiencies in intestinal BCMO1-mediated carotene to retinoid
conversion. The aim of this study is to identify potentially human-specific regulatory control
mechanisms of BCMO1 gene expression.
Results: We identified and functionally characterized the human BCMO1 promoter sequence and
determined the transcriptional regulation of the BCMO1 gene in a BCMO1 expressing human
intestinal cell line, TC-7. Several functional transcription factor-binding sites were identified in the
human promoter that are absent in the mouse BCMO1 promoter. We demonstrate that the
proximal promoter sequence, nt -190 to +35, confers basal transcriptional activity of the human
BCMO1 gene. Site-directed mutagenesis of the myocyte enhancer factor 2 (MEF2) and peroxisome
proliferator-activated receptor (PPAR) binding elements resulted in decreased basal promoter
activity. Mutation of both promoter elements abrogated the expression of intestinal cell BCMO1.
Electrophoretic mobility shift and supershift assays and transcription factor co-expression in TC-7
cells showed MEF2C and PPARγ bind to their respective DNA elements and synergistically
transactivate BCMO1 expression.
Conclusion: We demonstrate that human intestinal cell BCMO1 expression is dependent on the
functional cooperation between PPARγ and MEF2 isoforms. The findings suggest that the
interaction between MEF2 and PPAR factors may provide a molecular basis for interspecies
differences in the transcriptional regulation of the BCMO1 gene.
Background
Vitamin A, an essential micronutrient, is required for
embryonic development and pattern formation, postnatal
growth, reproduction, epithelial maintenance, immunity
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and vision [1-5]. With the exception of the retina, where
11-cis-retinal acts as the chromophore for rhodopsin [6],
biological activities of vitamin A are largely mediated by
isomers of retinoic acid (RA). RAs bind members of the
RA receptor (RAR) and retinoid X receptor (RXR) families
of ligand-dependent transcription factors to regulate tran-
scriptional rates of retinoid response genes. Vitamin A
deficiency is associated with histological abnormalities in
epithelial tissues [7], decreased host resistance to tumor
cells and infectious organisms [8], and increased suscepti-
bility to environmental carcinogens [9].
Animals, incapable of synthesizing vitamin A de novo from
isoprenoid precursors, require dietary intake of preformed
vitamin A, largely as retinyl esters, or must derive retinoids
from metabolism of plant β-carotene and related caroten-
oids. In humans, provitamin A carotenoids contribute
40–80% of total vitamin A stores [10]. Conversion of β-
carotene to vitamin A is catalyzed by the enzyme β, β-car-
otene 15,15'-monooxygenase (E.C. 1.13.11.21., BCMO1)
[11,12]. The structurally related β-carotene 9',10'-oxygen-
ase (BCMO2) catalyzes the quantitatively minor eccentric
cleavage of β-carotene to β-apo-10'-carotenal, retinol and
β-ionone [13,14].
In rodents, nearly all absorbed β-carotene is converted to
retinol in the intestine [15] except at very high doses [16].
In contrast, humans convert only a portion of ingested β-
carotene to vitamin A so that up to 15–30% of absorbed
β-carotene remains intact [17-19] and is delivered to tis-
sues. Several lines of evidence suggest that intestinal
BCMO1 activity is subject to transcriptional regulation
[20,21]. However, the mechanisms governing species-spe-
cific differences in efficiency of dietary β-carotene to retin-
oid cleavage remain unclear.
The human BCMO1 cDNA encodes a 63-kDa protein with
homologies to members of a large and diverse family of
polyene chain oxidases and carotenoid cleavage enzymes
[22,23]. Although BCMO1 can be detected in several tis-
sues, its expression is most pronounced in intestinal
mucosa and liver [24]. BCMO1 expression is downregu-
lated in rat intestine by β-carotene and RA [20]. In addi-
tion, recent data demonstrated that peroxisome
proliferator-activated receptor γ (PPARγ) regulates tran-
scription of the mouse BCMO1 gene [21]. The human
BCMO1 promoter sequences required for regulation of
BCMO1 gene expression have not previously been
defined.
We have isolated and characterized the human BCMO1
promoter region and identified several functional cis-act-
ing elements. We report that in the human, unlike murids,
myocyte enhancer factor 2 (MEF2) and PPAR transcrip-
tion factors interactively regulate intestinal cell BCMO1
gene expression. These data suggest that cooperation
between MEF2 and PPAR factors may provide a molecular
basis for the species differences between rodent and
human in the transcriptional regulation of BCMO1 gene.
Results
Identification of cis-acting elements in the BCMO1 
promoter
Computational analysis of putative cis-acting elements
located within the ~1.0 kb human BCMO1 5'-flanking
sequence was performed using the TRANSFAC database
[25] and TESS program. Several potential cis-acting ele-
ments were identified including, but not limited to, puta-
tive binding sites for CRE, RAR, MEF2, C/EBP, IRF1,
GATA1, AP2 and PPAR, and a TATA box (Additional File
1, A). Since the mouse BCMO1 gene is regulated by PPARγ
[21], initially we examined functionality of the PPAR
binding sequence in the human promoter. Comparison
between the human and mouse BCMO1 ~1.0 kb of
genomic 5'-flanking sequences revealed approximately
33% homology with considerable gaps (Additional file 1,
B). Several potential protein-DNA binding sites including
those for IRF1, GATA1, AP2, PPAR and TATA are present
in the same sequential order in the human and mouse
BCMO1 promoters.
Functional analysis of human BCMO1 basal promoter 
activity in TC-7 cells
To evaluate the functionality of these potential cis-acting
elements, the ~1.0 kb nucleotide sequence upstream from
the human BCMO1 coding sequence start site was excised
from pBCO1022-CR (Additional File 1, A) and ligated
into the pGL3-basic luciferase reporter vector (pGL3-
BCO1022). To determine whether this sequence confers
promoter activity, several cell lines including TC-7 were
transiently transfected with the pGL3-BCO1022 reporter
(data not shown). The human intestinal CaCo-2 derived
TC-7 cell line is unusual in that it has significant endog-
enous BCMO1 activity [26]. We also have determined by
RT-PCR that the parent CaCo-2 cell line expressed
BCMO1 mRNA, although at very low levels (data not
shown). Figure 1A shows this cloned DNA fragment
drives enhanced luciferase expression in TC-7 cells.
To map the region in the BCMO1 gene that influences
expression of the luciferase reporter construct, the ~1.0 kb
promoter sequence was progressively deleted from the 5'-
end by nested PCR to generate the deletion clones pGL3-
BCO682, pGL3-BCO328, pGL3-BCO218, pGL3-BCO147
and pGL3-BCO59. Each construct was transfected into
TC-7 cells. The expression vector pCMV-β-Gal was used as
an internal control for adjusting transfection efficiency. As
shown in Fig. 1B, deletion of the 5'-flanking 340 bp (-647/
+35 promoter fragment) minimally changed luciferase
activity compared to the full-length, -987/+35 genomicBMC Molecular Biology 2006, 7:7 http://www.biomedcentral.com/1471-2199/7/7
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Mapping of the regulatory elements in the BCMO1 promoter in TC-7 cells Figure 1
Mapping of the regulatory elements in the BCMO1 promoter in TC-7 cells. A. Transactivating activity of human 
BCMO1 promoter. A 1022-bp fragment was used for the construction of the BCMO1 reporter plasmid, pGL3-BCO1022, as 
described in "Methods". Luciferase activity was measured in total cell extracts obtained from TC-7 cells 24 h after transient 
transfection and compared with cellular luciferase activity for transfection of the control empty vector, pGL3-basic. B. Above, a 
schematic diagram of the BCMO1 promoter reporter construct (pGL3-BCO1022) showing the location of putative transcrip-
tion factor binding sites. Below, deletion analysis of the BCMO1 -987/+35 promoter fragment. TC-7 cells were transiently 
transfected with luciferase reporter constructs containing serial deletions of BCMO1 5'-flanking DNA. Cells were transfected 
with reporter constructs (0.3 μg/well) and a β-Gal expression vector was added as an internal control. After 24 h, cells were 
lysed and luciferase and β-Gal activities were measured. Results are means ± S.D. of three or more independent experiments 
each performed in triplicate. *, p < 0.05, **, p < 0.001.
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fragment. Further deletions of the 5'-flanking sequence (-
293/+35 and -197/+35) progressively decreased luciferase
activity by 25-30%. Deletion of an additional 5'-flanking
85 bp (-112/+35 promoter sequence) that includes puta-
tive MEF2, C/EBP and IRF1 sites, dramatically decreased
reporter gene expression. Further deletion completely
abolished BCMO1 reporter activity. As a negative control,
TC-7 cells transfected with empty vector (pGL3-basic)
showed no significant luciferase activity. Transfection of
the minimal promoter fragment (pGL3-BCO147) con-
taining the PPAR site (-55/-43) resulted in an approximate
12-fold induction of luciferase activity compared with the
pGL3-basic vector (Figure 1B).
MEF2 and PPAR sites in the BCMO1 promoter and basal 
transcription
The ~200 bp genomic DNA region proximal to the tran-
scriptional start site was further investigated to determine
which specific cis-acting elements confer basal expression
of the human BCMO1 gene. Sequence analysis suggested
the presence of a MEF2 binding site (TGCTTATTTAGA)
(Additional file 1, A) that is absent in the mouse pro-
moter, and a PPAR/RXR binding site (TAACCTTTAACCA)
conserved in the mouse promoter. Therefore, the MEF2
site was mutated (Figure 2A) to test its contribution to
basal transcriptional activity. As shown in Figure 2B,
transfection of a reporter construct containing the
mutated MEF2 binding site resulted in an approximately
30% reduction in luciferase activity compared to the wild
type construct, pGL3-BCO218. A much greater reduction
in reporter gene activities (pGL3-BCO218 and pGL3-
BCO147) resulted from mutation of the PPAR site lying
within the proximal promoter sequence. Mutation of
both MEF2 and PPAR sites within the proximal promoter
region of BCMO1 (pGL3-BCO218) abrogated the expres-
sion of reporter gene.
Verification of MEF2 and PPAR binding to the BCMO1 
promoter
The following experiments were undertaken to verify that
endogenous transcription factors bind to these different
BCMO1 proximal promoter response elements. As shown
in the Western blots reproduced in Additional file 2A, TC-
7 cell nuclear extracts contain PPAR isoforms (PPARα, β
and γ), RXRα, RARβ and MEF2 isoforms (MEF2A, 2C and
2D). The capacity of MEF2 to bind the corresponding
BCMO1 elements was then tested using EMSA with TC-7
nuclear protein extracts and radiolabeled probes corre-
sponding to the wild type or mutated MEF2 binding
sequence (nt -188 to -165) (additional file 2B). A MEF2
DNA-protein complex was detected (Additional File 2C,
left panel) having electrophoretic mobilities correspond-
ing to heterodimeric or homodimeric MEF2 isoforms,
consistent with previously reported observations [27].
Specificity of MEF2 binding was verified by three criteria.
First, specific DNA-protein binding was eliminated by the
addition of 100-fold molar excess of the non-radiolabeled
specific oligonucleotide. Second, substitution of radiola-
beled oligonucleotide in which the MEF2 site was
mutated also abolished DNA-protein complex formation
(Additional File 2C, left panel). Finally, to further assess
the identity of TC-7 cell nuclear proteins binding to the
MEF2 site, supershift analysis was performed using spe-
cific MEF2 antibodies. The radiolabeled probe corre-
sponding to the MEF2 binding site was supershifted by
addition of an antibody to MEF2C to an extent that corre-
sponded to its abundance in TC-7 cell nuclei (Additional
file 2A). Supershift assays showed diminished intensity of
DNA-protein complex with antibody against MEF2A and
an appearance of a supershifted band with antibody
against MEF2D. (Additional file 2C, right panel).
Interrogation of the BCMO1 promoter PPAR-response
element (PPRE) (-60/-37) using EMSA yielded a single
PPRE DNA-protein band with the expected mobility
(additional file 2D, left panel). Similar to the MEF2 EMSA,
this binding was specific, as it was inhibited by addition
of excess cold specific oligonucleotide and abolished by
substitution of a mutated PPRE oligonucleotide probe
(additional file 2B and 2D, left panel). The specificity of
this interaction was further observed by the supershift
assay. Binding of members of the PPAR family of tran-
scription factors, RXR and RAR transcription factors was
demonstrated using the PPAR site (-60/-37) as a probe.
The results showed diminished intensity of the bound
lower band (relative to the upper band) with addition of
antibodies against PPARγ and RXRα as well as the appear-
ance of a weakly detectable supershifted band with addi-
tion of RXRα antibody (Additional file 2D, right panel).
The extent of supershift with PPARγ antibody corre-
sponded to its low abundance in TC-7 cell nuclei as
shown in Additional File 2A.
The region of the human BCMO1 promoter flanked by
the MEF2 (-185/-173) and AP2 (-69/-61) elements con-
tains a cluster of potential regulatory elements. A compar-
ison of this DNA region to the BCMO1 5'-flanking regions
in other currently sequenced genomes shows the MEF2
site (-185/-173) and a putative C/EBP site (-165/-155) are
uniquely present in the human BCMO1 promoter (data
not shown). The C/EBP DNA response element showed
specific transcription factor binding in TC-7 cells, but
DNA-protein binding did not significantly alter transcrip-
tional activity of the promoter reporter constructs (data
not shown). Putative IRF-1 and GATA1 binding sites in
this region are represented both in the aligned human and
mouse BCMO1 promoters. However, no specific protein
binding to either of these DNA elements in the TC-7 cell
system was detected (data not shown).BMC Molecular Biology 2006, 7:7 http://www.biomedcentral.com/1471-2199/7/7
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Cooperation of MEF2C and PPARγ/RXRα in intestinal 
BCMO1 promoter activity
As an alternative strategy for characterizing the depend-
ence of BCMO1 transcription on MEF2 and PPAR iso-
forms, in various experiments we co-transfected a
proximal BCMO1 reporter construct (pGL3-BCO218)
with mammalian expression vectors for MEF2C, PPARγ,
RXRα or PPARγ /RXRα, each of the latter under the control
of a cytomegalovirus or Rous sarcoma virus promoter.
Relative luciferase activity was normalized to that result-
Functional analysis of the BCMO1 promoter mutated regulatory sequences Figure 2
Functional analysis of the BCMO1 promoter mutated regulatory sequences. A. Comparison of wild type and 
mutant sequences for the BCMO1 promoter MEF2 binding site (-187/-163) and PPAR binding site (-61/-37). Mutated base pairs 
are underlined and in bold. B. Site-directed mutations (in solid black) were introduced into the binding sites of both MEF2 and 
PPAR transcription factors. TC-7 cells were transfected with 0.3 μg/well of luciferase reporter constructs containing BCMO1 
proximal promoter fragments of 218 bp or 147 bp in length or with the corresponding mutated sequences. Data are expressed 
as a relative fold luciferase activity compared to that of the empty vector. Results shown are means ± S.D. of three or more 
independent experiments each performed in triplicate. *, p < 0.05, **, p < 0.001.
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ing from co-transfection with the empty vector, pcDNA3.
Cells in which MEF2C was over-expressed showed an
approximately three-fold increase in relative luciferase
activity. Conversely, expression of a dominant negative
MEF2 (MEF2A-131) reduced activity of the BCMO1 pro-
moter reporter gene by half (Additional File 3A). As
shown in Additional File 3B, approximately 1.5, 1.4 and
three-fold increases in pGL3-BCO218 luciferase activity
were induced by PPARγ, RXRα and PPARγ /RXRα, respec-
tively. Surprisingly, co-expression of MEF2C plus PPARγ /
RXRα resulted in a six-fold stimulation of the BCMO1
reporter expression (Additional File 3B), indicating MEF2
and PPARγ have an additive effect on BCMO1 promoter
activity.
The role of the PPRE in the BCMO1 promoter sequence
was further probed using co-expression of PPARγ /RXRα
with the reporter construct containing the BCMO1 mini-
mal promoter sequence (pGL3-BCO147). This DNA frag-
ment contains the PPRE but lacks the MEF2 sites. The
resulting reporter gene activity was dramatically ampli-
fied. As a control condition, co-expression of PPARγ /
RXRα with this BCMO1 minimal promoter sequence in
which the PPRE was specifically mutated resulted in no
increase in luciferase activity (Additional File 3C).
To confirm the additive effects of MEF2C and PPARγ in
BCMO1 promoter activation, we utilized BCMO1 pro-
moter constructs in which the respective response ele-
ments were mutated. Wild type and mutated promoter
constructs were then co-transfected into TC-7 cells with
MEF2C or PPARγ /RXRα alone or in combination. As
shown in Additional File 3D, the wild type proximal pro-
moter (pGL3-BCO218) enhanced BCMO1 reporter activ-
ity when co-transfected with MEF2C, PPARγ /RXRα or the
combination of MEF2C and PPARγ /RXRα. Mutation of
the MEF2 site (pGL3-BCO218-mutMEF2), but not of the
PPAR site, significantly reduced this enhanced BCMO1
reporter expression by 24–30%. Conversely, mutation of
the PPRE (pGL3-BCO218-mutPPAR) not only dramati-
cally decreased basal BCMO1 promoter activity, but also
decreased the MEF2C and PPARγ-induced activation. The
combinatorial effects of MEF2C plus PPARγ /RXRα on the
BCMO1 reporter gene were abolished when either the
MEF2 site or PPAR site were mutated.
Discussion
Although the in vivo enzymatic reaction first was described
in 1930 by Moore [28], identification of β-carotene oxyge-
nase activity was only demonstrated in 1965 when Olsen
and Hayaishi [11] and Goodman and Huang [12] inde-
pendently showed rat small intestine homogenates enzy-
matically cleave β-carotene at the 15,15'-carbon double
bond to yield two molecules of vitamin A aldehyde (reti-
nal). More recently, this central cleavage enzyme,
BCMO1, was purified [29,30], mouse [31-33] and human
[34] cDNAs were identified and the human recombinant
enzyme was biochemically characterized [35] as a
monooxygenase [36].
Cleavage of β-carotene has been shown to be a source of
target tissue retinoic acid production in the small intes-
tine, liver, kidney, lung and testis [37]. In addition to con-
siderable apparent tissue-specific regulation [[20],
unpublished data], BCMO1 is subject to species differ-
ences in the efficiency of intestinal β-carotene to retinoid
cleavage. The goal of the current studies was to identify the
basal promoter and core transcriptional elements respon-
sible for regulating human BCMO1 expression in intesti-
nal cells. The use of CaCo-2 derived TC-7 cells was
prompted by their demonstrated endogenous BCMO1
activity. TC-7 cells have a phenotype even closer to small
intestine enterocytes than does the parental population
gauged by expression of several additional differentiation-
associated proteins and nutrient absorption patterns
[38,39].
The comparison of the human and mouse promoter
sequences by ClustalW and manual inspection revealed
little interspecies homology. Whether this finding is rele-
vant to the marked species differences in carotenoid
absorption and metabolism is not known. In humans,
although the majority of absorbed β-carotene can be con-
verted in the intestine directly to retinal [17,18,40], con-
siderable  β-carotene levels are detected in blood. In
rodent small intestine, nearly all β-carotene is directly
cleaved to retinal, leaving little intact β-carotene in the cir-
culation.
Recent data emphasize the concept that interspecies
expression differences, especially in structural genes such
as enzymes, are less the result of select trans-regulatory
changes with widespread effects, but rather of many cis-
acting changes spread throughout the genome [41,42].
The sequence context of the genomic DNA regions that
contain protein-binding sites may determine whether
these regions function in transcriptional regulation. Since
closely spaced transcription factor binding sites can facili-
tate protein-protein interactions, clustering of protein-
binding elements is often a hallmark of a subset of the
control regions in genomic DNA [43-46].
We found the proximal 700 bp of genomic 5'-flanking
sequence conferred maximal BCMO1 promoter activity in
a homologous human intestinal cell system. Our func-
tional studies (promoter deletion experiments, site-
directed mutagenesis assays, EMSA, supershift, ability to
drive expression of reporter genes) establish that the min-
imal region of the human BCMO1 promoter required for
induction of the gene is located within 200 bp upstreamBMC Molecular Biology 2006, 7:7 http://www.biomedcentral.com/1471-2199/7/7
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from the start site of transcription, a region that contains
a cluster of cis-acting elements. Mutation of the PPRE or
MEF2 binding sites reduced basal promoter activity.
Mutation of both promoter elements abrogated BCMO1
transcription in intact cells, a result additive of the effects
of mutating either site singly. Coupled with the direct
experimental confirmation of specific binding, the PPRE
and the human-specific MEF2 site together regulate basal
BCMO1 expression. This result differs from the mouse, in
which the PPRE solely is both necessary and sufficient for
the restricted expression of BCMO1 [21].
The MEF2 family of transcription factors was initially
identified from muscle cells due to binding to an A/T rich
consensus sequence [c/tTA(A/T4)TAg/a] found in the reg-
ulatory region of many muscle specific genes [47]. It since
has become apparent that MEF2 transcription factors par-
ticipate in diverse gene regulatory programs, including
those for muscle and neural differentiation, cardiac mor-
phogenesis and blood vessel formation [48]. Four mam-
malian isoforms of MEF2 (A to D), encoded by separate
genes, have been identified [47]. However, although
MEF2 has been shown to play important roles in several
cell types including skeletal muscle, neurons, T cells and
other non-muscle cells [48-50], to our knowledge, a role
for MEF2 has not previously been described in intestinal
epithelial cells. In the present work, we provide evidence
that three isoforms of MEF2 (MEF2A, C and D) are
expressed in intestinal TC-7 cells (Additional file 2A). Iso-
forms of MEF2 have been studied in several biological sys-
tems, including muscle, neurons, and immune cells,
where multiple isoforms are present [48]. Whether differ-
ent isoforms of MEF2 present in the same cell may per-
form distinct molecular functions remains largely
unknown. Complexity arises from the observations that
different isoforms of MEF2 can form either heterodimers
or homodimers having apparently indistinguishable
DNA-binding specificity. Our data show MEF2C is the
major MEF2 isoform that binds to BCMO1 promoter.
Consistent with this observation, our data showed that
over-expression of MEF2C significantly transactivated
BCMO1 reporter gene activity in TC-7 cells.
MEF2 proteins interact with and potentiate the action of
other classes of lineage-specific transcription factors. In
the present study, we also demonstrated that MEF2C and
PPARγ cooperatively regulate BCMO1 gene expression, an
observation reminiscent of the interaction between MEF2
proteins and myogenic bHLH factors in skeletal muscles.
Several studies have reported functional interaction
between MEF2 proteins and members of the nuclear
receptor superfamily, such as MEF2A and thyroid hor-
mone receptor (TR) synergism to activate α-cardiac MHC
gene expression [51] and MEF2C and PPARα cooperation
to induce human carnitine palmitoyltransferase 1β
(CTB1β) gene activation [52]. Given the co-expression of
MEF2 and PPAR factors in several cell types including
intestinal epithelial cells, the PPAR-dependent MEF2
pathway described in this work may provide a molecular
paradigm for understanding the mechanism of action of
MEF2 in many target cells.
Changes in expression magnitude and relative expression
of genes can be a governing mechanism driving species
diversification [42] via adaptation to ecological, including
nutritional, niches. The importance of BCMO1 gene
expression in the maintenance of vitamin A sufficiency
makes the BCMO1 promoter a likely target for natural
selection. Interspecies differences in efficiency of β-caro-
tene metabolism raise the question whether different
regions of the BCMO1 promoter have evolved under het-
erogeneous dietary constraints. The limitations of the
present study preclude associating the human specific reg-
ulation of BCMO1 with specific metabolic consequences.
Nevertheless, our data suggest physiological hypothesis as
only certain DNA sequences functional for the binding of
activators are conserved.
Further investigation should advance the understanding
of transcriptional control of the key step in β-carotene to
vitamin A conversion and, consequently, may have rele-
vance for physiology and human health.
Conclusion
We showed that the proximal ~200 bp of BCMO1 pro-
moter region is essential for basal promoter activity of
human BCMO1 in intestinal TC-7 cells. PPARγ is essential
but not sufficient to activate human BCMO1 gene expres-
sion. BCMO1 expression is dependent on the cooperation
between PPARγ and MEF2 isoforms. An understanding of
the transcription factors and cis-acting elements involved
in regulation of the human BCMO1 expression should
facilitate a better understanding of the regulation of
BCMO1 expression in physiologic and pathologic states
of Vitamin A formation.
Methods
Cell line, reagents and plasmids
Clone TC-7 [53] of the human intestinal Ca Co-2 parent
cell line was obtained from Dr. Alexandrine During,
USDA Human Nutrition Research Center, Beltsville, MD.
The PPARγ agonist (GW1929) and antagonist (GW9662),
PPARα agonist (WY14643) and antagonist MK886, and
PPARβ agonist (GW501516) were obtained from Alexis
Biochemicals (San Diego, CA). The PPARα, PPARβ and
PPARγ expression vectors were the gifts of Dr. D.P. Kelly
(Washington University School of Medicine, St. Louis,
Mo.). The RXRα, RARβ and β-galactosidase (β-Gal)
expression vectors were gifts of Dr. P. Lefebvre (Ligue
Nationale Contre le Cancer, Paris, France). The MEF2CBMC Molecular Biology 2006, 7:7 http://www.biomedcentral.com/1471-2199/7/7
Page 8 of 12
(page number not for citation purposes)
and MEF2A-131 (dominant negative form of MEF2,
DnMEF2) expression vectors were gifts from Dr. Zixu Mao
(Brown Medical School, Providence, R.I.).
Cloning of the 5'-flanking region of the human BCMO1 
gene
A 1022 bp BCMO1 promoter fragment spanning nt
79828775 to 79829795 [Ensembl Gene,
ENSG00000135697] [54] was amplified by the polymer-
ase chain reaction (PCR) from human liver genomic DNA
(BioChain Institute, Hayward, CA) using a 5' primer, 5'-
GAATTTCAGGCAATGGCAAC-3' (corresponding to
genomic DNA sequence nt 79828775 to 79828795) and
a 3' primer, 5'-ACTTGTCCCTCTCCAAGAGC-3' (corre-
sponding to nt 79829775 to 79829795). The PCR product
was gel purified and ligated into pCR2.1 using a TA Clon-
ing Kit (Invitrogen Corp., Carlsbad, CA) to create
pBCO1022-CR. Orientation was confirmed by DNA
sequence analysis.
Construction of luciferase plasmids
The plasmid pGL3-basic (Promega Corp.) was used to
construct pGL3-BCO1-Luc plasmids containing BCMO1
promoter fragments. pGL3-BCO1(-987/+35)-Luc, con-
taining the DNA 5'-flanking sequence nt -987 to +35 (rel-
ative to the transcription start site [+1]), was excised from
pBCO1022-CR by double digestion with KpnI and XhoI,
ligated into the KpnI/XhoI sites of pGL3-Basic using T4
DNA ligase and sequenced to verify orientation. This full-
length reporter plasmid was designated pGL3-BCO1022.
To generate progressive 5'-unidirectional deletion
mutants by PCR, a series of forward primers was used in
combination with the same reverse primer and pGL3-
BCO1022 as template. The reverse primer (with the XhoI
site underlined) was 5'-CCGCTCGAGGGTGCCGAGGGA-
GATC-3'. The forward primers, each of which included the
KpnI restriction site (underlined), began with: -647 (5'-
CGGGGTACCGGTCTCGAACTCCTG); -293 (5'-CGGGG-
TACCTAATTCCCAGCACCTC); -197 (5'-CGGGGTACCG-
GAATTCTCTCTGC); -112
(5'CGGGGTACCAAAGCTGAGGGC); and -24 (5'-
CGGGGTACCAGCGCAGCTTCCCTTG). The PCR prod-
ucts were gel-purified, digested with KpnI and XhoI, and
subcloned into the KpnI/XhoI sites of pGL3-Basic. They
were designated pGL3-BCO682, pGL3-BCO328, pGL3-
BCO218, pGL3-BCO147 and pGL3-BCO59, respectively.
Each construct was verified by sequencing the insert and
plasmid flanking region.
Site-directed mutagenesis
To generate site-directed mutants of the cAMP response
element-binding protein (CREB), RAR, MEF2, CCAAT/
enhancer binding protein (C/EBP) and PPAR DNA ele-
ments that are located from nt -647 to -56, the Quick-
Change site-directed mutagenesis kit (Stratagene, La Jolla,
CA) was used according to the manufacturer's instruc-
tions. The oligonucleotides used to create the mutations
are listed in Table 1, with the mutated nucleotides in bold
and  underlined  throughout (The complementary strand
sequences are not shown). Mutation of each binding
sequence was confirmed by DNA sequencing.
Transient transfection and luciferase assays
The TC-7 subline of CaCo-2 cells was cultured in Dul-
becco's Modified Eagle's Medium (DMEM, Life Technolo-
gies Inc., Gaithersburg, Md.) supplemented with
penicillin (100 units/ml), streptomycin (100 μg/ml) (Life
Technologies), and 20% fetal bovine serum (HyClone,
Logan, Ut.) at 37°C in a humidified atmosphere of 95%
air and 5% CO2. Cells were plated in 12-well tissue culture
dishes at a density of 5 × 104 cells/well for 24 h before
transfection. At 70–90% confluence, cells were transfected
with 0.3 μg of the indicated constructs using 1 μl of Lipo-
fectAMINE 2000 transfection reagent per well mixed in
Opti-MEM I (Invitrogen). Co-transfection with a β-galac-
tosidase expression plasmid was used to determine effi-
ciency of each transfection. For the co-transfection assays,
the total amount of DNA for each transfection was kept
constant by using a control vector (pcDNA3). At various
time points, cell lysates were analyzed for luciferase and β-
galactosidase activities. Luciferase activity relative to the
pGL3-basic transfectants was determined after adjustment
for β-galactosidase level. All transfections were performed
in triplicate for at least three independent experiments.
Electrophoretic mobility shift assay (EMSA)and supershift 
assays
Nuclear extracts from TC-7 cells were prepared as
described previously [21]. Double-stranded oligonucle-
otides containing sequences from the human BCMO1
promoter (shown in Table 2) were synthesized (Operon
Biotechnologies, Inc., Huntsville, Ala.). EMSA reaction
mixtures (20 μl final volumes) included 5–15 μg of
nuclear extract, 25 mM HEPES, 100 mM KCl, 0.1% Noni-
det P-40 (v/v), 1 mM dithiothreitol, 5% glycerol and 1 μg
of poly(dI-dC) (Sigma, St. Louis, Mo.) as a nonspecific
competitor. After incubation for 20 min on ice, 20 fmol of
[γ-32P]-ATP end-labeled probe was added and the reaction
was incubated for 30 min at room temperature. Protein-
Table 1: Oligonucleotides used in PCR-based site-directed 
mutagenesis
Primer sequence Mutated sitea
5'-GGAAATTAACGCTTAACCAAAC-3' PPAR/RXR -52/-50
5'-TAGTCTGAAAGTAGCTTTT-3' C/EBP -161/-159
5'-TCTGCTTCTTTACAACCTAGTCTG-3' MEF2 -179/-174
5'-ACTCCTGTGCTCAAGTGTGCCG-3' CRE/RAR -633/-623
a Initiation site for BCMO1 transcription, +1. The mutated nucleotides 
are in bold.BMC Molecular Biology 2006, 7:7 http://www.biomedcentral.com/1471-2199/7/7
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DNA complexes were separated on a 5% non-denaturing
polyacrylamide gel in 0.5 × Tris-borate-EDTA buffer at
25°C. For competition assays, 100-fold molar excess of
unlabeled double-stranded oligonucleotide competitor
was incubated together with the nuclear extract prior to
adding the 32P-labeled probe. For supershift EMSA, anti-
bodies were preincubated with the nuclear extract mix-
tures in the binding reaction for 20 min before the probe
was added.
Western blot analysis
TC-7 cells were harvested, lysed in 1 ml of phosphate-
buffered saline (PBS) containing 1% Triton X-100, 0.1%
SDS, 1 mM dithiothreitol and 1 mM phenylmethylsulfo-
nyl fluoride and centrifuged at 1,500 × g for 5 min. Protein
concentrations were determined by the BCA protein assay
(Pierce Biotechnology, Inc., Rockford, Il.), and 40 μg cell
lysate samples were fractionated by SDS-PAGE. Proteins
were transferred to Immobilon-P membranes (Millipore,
Billerica, MA) by semi-dry blotting. The membrane was
treated according to a standard Western Blotting protocol
with chemiluminiscence detection. Rabbit polyclonal
MEF2C (Cell Signaling Technology, Inc., Beverly, Mass.),
MEF2D (BD Transduction Laboratories, Lexington, Ky.),
MEF2A, PPARα, PPARβ, PPARγ, RARα and RXRα (Santa
Cruz Biotechnology, Santa Cruz, CA) antibodies were
diluted to 1:500 to 1:1000 in PBS, 5% non-fat dry milk.
Protein-antibody interactions were detected by enhanced
chemiluminescence (Amersham Biosciences Corp., Pis-
cataway, NJ).
Statistics
Each experiment was performed in triplicate, and the
reporter values represent the mean of three to five separate
cultures ± standard deviation. The significance of the dif-
ference was determined using Student's t test.
Abbreviations
BCMO1,  β,  β-carotene 15, 15'-monooxygenase 1; RA,
retinoic acid; RAR, retinoic acid receptor; RXR, retinoid X
receptor; C/EBP, CCAAT/enhancer-binding protein;
MEF2, myocyte enhancer factor 2; PPAR, peroxisome pro-
liferator-activated receptor; PPRE, PPAR-response ele-
ment; EMSA, electrophoretic mobility shift assay;
Authors' contributions
X.G.: performance and interpretation of all experiments
and manuscript preparation; S.T.: participation in the
planning of the study; B.Y.: support to X.G.s' experiments;
L.P.R.: conceived the study, design and coordination of
the study, manuscript preparation. All authors read and
approved the final version of the manuscript.
Additional material
Additional file 1
Identification of human BCMO1 promoter
A. Nucleotide sequence of the human β, β-carotene 15,15’-monooxygen-
ase 1 (BCMO1) promoter. Nucleotides are numbered relative to the tran-
scriptional start site (+1) [34]. Potential consensus sequences for 
transcription factor binding sites are underlined and labeled. The 
sequence was analyzed according to the TESS program and TRACSFAC 
transcription factor database.
B. Alignment of ~900-bp of human and mouse proximal BCMO1 
genomic sequence by the ClustalW (1.82) program [55]. The numbering 
is relative to the transcription initiation site (+1). The sequences in bold 
and labeled indicate putative DNA regulatory elements common to the 
two promoters.
Click here for file
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Table 2: Oligonucleotides used for EMSA for putative binding sites
Oligonucleotide sequencea DNA element
5'-GCTTGGAAATTAACCTTTAACCAAACAT-3' Wild-type PPAR
5'-GCTTGGAAATTAtgCTTTAtgCAAACAT-3' Mutated PPAR
5'-GGATTAAAGATTAGCTATGACACCATG-3' Wild-type GATA-1
5'-GGATTAActcTTAGCTATGACACCATG-3' Mutated GATA-1
5'-GGTTAAGTCAAAAGTGAAACTGGAG-3' Wild-type IRF-1
5'-GGTTAAGTCAtcAGTGAAACTGGAG-3' Mutated IRF-1
5'-CTCTCTGCTTATTTAGAACCTAGTC-3' Wild-type MEF2
5'-CTCTCTGCTTgTTTAcAACCTAGTC-3' Mutated MEF2
5'-GAACTCCTGACCTCAAGTGACCCGCCAC-3' Wild-type CRE/RAR
5'-GAACTCCTGtgCTCAAGTGtgCCGCCAC-3' Mutated CRE/RAR
a Upper strands of oligonucleotides with putative consensus sequences are underlined; the mutated nucleotides are in lower case characters.BMC Molecular Biology 2006, 7:7 http://www.biomedcentral.com/1471-2199/7/7
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